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There remains substantial evi-
dence to warrant great concern
over the poor efficiency and
specificity of clustered regularly
interspaced short palindromic re-
peats (CRISPR)-mediated genetic
modification (GM), despite rela-
tively minor improvements com-
pared to other GM methods.
These issues cause persistent,
adverse, ethical, and scientific
consequences for GM animals,
which may never be sufficiently
resolvable.
An article recently published in Trends in
Biotechnology discussed how engineering
of guide RNAs could improve the effi-
ciency and specificity of CRISPR [1].
While this technique may have great
potential for aiding research into the
understanding of gene function in the
future, and for eventual clinical applica-
tions, such as gene therapy, the authors
may have been over-optimistic and
speculative, and insufficiently critical.
While they acknowledge some caveats
(only a small set of target genes has
been investigated), and the need for
further improvements (in increasing
efficiency, specificity, and obviating
toxicity), it is important to provide
more balance, as there exists significant
evidence warranting great caution on
several levels, which seems underappre-
ciated. This is particularly relevant to
the creation of GM animals, which
will be an area in which CRISPR is
heavily used, and for which there are
serious ethical/welfare consequences
and considerations.
I recently questioned claims about
CRISPR’s high degree of efficiency and
specificity, and reviewed the evidence
supporting amuchmore prudent approach,
which is urged by some stakeholders [2]. To
illustrate, recent reports have highlighted
slightly improved, though still very poor
efficiencies, which when one looks for preci-
sion, amount to a few percent at most [3].
Off-target effects are persistent, even with
engineered CRISPR components, and can
have multiple pathogenic consequences,
including cancer. Many off-target effects
are missed due to analytical methods
that aren’t sufficiently comprehensive, and
– crucially – some believe they may never
be completely removed, however high on-
target specificity may become [4,5]. On-
target effects may often be more significant
than intended, causing large deletions and
genomic rearrangements. CRISPR is also
more likely to be successful in cells in
which the p53 gene is deficient, and so
has further cancerous potential – with cata-
strophic consequences for GM animals
and for clinical applications [6,7]. This tumor-
igenicity does not arise solely from CRISPR,
so other contributory factors must be
identified. While cells could be selected to
avoid this, it is not possible for in vivo appli-
cations. Perhaps alarmingly, these issues
have not led to the cautious approach they
justify, and which some scientists urge.
This is partly evidenced by clinical trials of
the technology, which has been used for
various malignancies/cancers.
These concerns are in addition to other
long-standing problems associated with
the creation of, and experimentation on,
GM animals. While these issues could not
be expected to be addressed by the au-
thors of the recent Trends in Biotechnology
paper, they are relevant to the use of
CRISPR in science, and substantiate the
call for a much more cautious attitude.
Poor efficiency and specificity are acknowl-
edged to be a serious welfare issue, with
every stage of the creation and breeding of
GM animals potentially involving pain and
suffering to some degree, and which may
not be fully appreciated and taken into ac-
count in harm–benefit analyses [8,9]. There
exists significant evidence of failed transla-
tion of data from GM animals to human
benefit, and of their poor human relevance
for many diseases [2]. Of salient concern
currently is the increased creation of, and
experimentation on, GM monkeys, partly in
response to greater appreciation of the
inadequacies of GM mice. It has been
suggested that they will be more human
relevant, but there is little or no evidence to
support this. They will be subject to the
same inefficiencies and lack of specificity
as GM mice, due to the aforementioned
(and possibly persistent) inadequacies of
CRISPR, and there are myriad confounding
differences in gene complement and ex-
pression between humans and monkeys,
which will always affect – and preclude –
their applicability to humans [10].
Finally, it is important to note that many who
oppose the application GM technology to
animals for ethical and scientific reasons,
do not oppose its use in basic science in-
volving cell and tissue cultures, which will
become more informative and human rele-
vant with further advances in 3D culture,
organoids, body-on-a-chip approaches,
stem cells, and so on. These techniques
are already being used to investigate gene
function, link genetic mutations/polymor-
phisms with phenotype, attempt gene ther-
apy, etc. It is these human relevant in vitro
methods that will determine if CRISPR can
be sufficiently safe and reliable to be used
in human patients (along the lines that
Moon and colleagues [1] suggest). There is
no scientific necessity to develop CRISPR
in animals, or scientific basis to assume
that successful and 'safe' gene therapy in,
say, mice or monkeys, will translate to the
same in human patients.
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